NCT00725075View on ClinicalTrials.gov

Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)

PHASE2CompletedINTERVENTIONAL

Enrollment

215

Participants

Timeline

Start Date

April 10, 2007

Primary Completion Date

October 24, 2008

Study Completion Date

October 24, 2008

Conditions

Schizophrenia

Interventions

DRUG

MK-8435 (Org 25935) 4-8 mg

Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day

DRUG

Placebo

Matching placebo for MK-8435 (Org 25935) administered orally BID

DRUG

MK-8435 (Org 25935) 12-16 mg

Administered orally BID for a final concentration of 24-32 mg/day

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00725075 - Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) | Biotech Hunter | Biotech Hunter